Skip to main content

San Antonio Breast Cancer Symposium 2020


Expert video interviews

Latest research news

22-12-2020 | SABCS 2020 | Conference coverage | News

​​​​​​​TNBC patients benefit from pembrolizumab in combination with various chemotherapies

Beneficial outcomes with pembrolizumab plus chemotherapy persist with different types of chemotherapy in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer, exploratory analysis of the KEYNOTE-355 trial suggests.

17-12-2020 | SABCS 2020 | Conference coverage | News

Palbociclib use does not extend IDFS for high-risk breast cancer patients

The PENELOPE-B investigators have found no invasive disease-free survival benefit with a 1-year course of palbociclib alongside endocrine therapy for hormone receptor-positive breast cancer patients who did not achieve a complete pathologic response to neoadjuvant chemotherapy.

16-12-2020 | SABCS 2020 | Conference coverage | News

Integrated tool may individualize prognosis prediction in early breast cancer

A prognostic tool that integrates clinicopathologic and genomic data provides more information on distant recurrence risk than either feature alone, and can estimate absolute chemotherapy benefit in individual patients with node-negative breast cancer, say researchers.

Medicine Matters conference coverage is brought to you in partnership with medwireNews

Image Credits